Enasidenib and ivosidenib, IDH2 and IDH1 inhibitors respectively, were developed by Agios Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of adult relapsed or refractory AML with IDH2 and IDH1 mutations [65,66]. The gene discussed is IDH1; the disease is acute myeloid leukemia.